FDA Says Issues Warning To AcelRx For 'Making False And Misleading Claims About Risks And Benefits Of Dsuvia;' Says Co Disseminated Promotional Communications That Undermine Key Prescribing Conditions Required For Safe Use Of Its Opioid Product